AN2 Therapeutics Inc.
| NASDAQ: ANTX | Healthcare / Biotechnology / USA |
| 13.66 | -0.1500 | -1.09% | Vol 35.99K | 1Y Perf 23.30% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 12.34 | ASK | 15.50 | ||
| Open | 13.78 | Previous Close | 13.81 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 23.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 70.79 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 54.36 | Earnings Rating | — | |
| Market Cap | 299.54M | Earnings Date | 8th Nov 2023 | |
| Alpha | 0.06 | Standard Deviation | 0.40 | |
| Beta | 0.03 |
Today's Price Range 13.1314.00 | 52W Range 4.8721.04 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -7.26% | ||
| 1 Month | -9.24% | ||
| 3 Months | 83.36% | ||
| 6 Months | 26.01% | ||
| 1 Year | 23.30% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -32.10 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -30.81 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -32.79 | |||
Return on invested Capital Q | -10.66 | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.40 | ||||
| 1.86 | ||||
| - | ||||
| - | ||||
| -7.60 | ||||
| -1.79 | ||||
| 1.86 | ||||
| 5.44 | ||||
| 92.24M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 23.60 | ||||
| 24.20 | ||||
| - | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.85 | -0.81 | 4.71 |
| Q01 2023 | -0.68 | -0.79 | -16.18 |
| Q04 2022 | -0.63 | -0.61 | 3.17 |
| Q03 2022 | -0.59 | -0.59 | 0.00 |
| Q02 2022 | -0.45 | -0.53 | -17.78 |
| Q01 2022 | -0.52 | -2.98 | -473.08 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 8th Nov 2023 |
| Estimated EPS Next Report | -0.80 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 35.99K |
| Shares Outstanding | 21.93K |
| Shares Float | 12.92M |
| Trades Count | 374 |
| Dollar Volume | 496.38K |
| Avg. Volume | 108.28K |
| Avg. Weekly Volume | 141.85K |
| Avg. Monthly Volume | 83.41K |
| Avg. Quarterly Volume | 99.57K |
AN2 Therapeutics Inc. (NASDAQ: ANTX) stock closed at 13.66 per share at the end of the most recent trading day (a -1.09% change compared to the prior day closing price) with a volume of 35.99K shares and market capitalization of 299.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. AN2 Therapeutics Inc. CEO is .
The one-year performance of AN2 Therapeutics Inc. stock is 23.3%, while year-to-date (YTD) performance is 43.34%. ANTX stock has a five-year performance of %. Its 52-week range is between 4.87 and 21.0399, which gives ANTX stock a 52-week price range ratio of 54.36%
AN2 Therapeutics Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 1.86, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.81%, a ROC of -32.79% and a ROE of -32.10%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AN2 Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.80 for the next earnings report. AN2 Therapeutics Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for AN2 Therapeutics Inc. is Strong Buy (1), with a target price of $23.33, which is +70.79% compared to the current price. The earnings rating for AN2 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AN2 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AN2 Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.98, ATR14 : 1.11, CCI20 : -115.36, Chaikin Money Flow : 0.00, MACD : 0.59, Money Flow Index : 32.51, ROC : -14.63, RSI : 51.26, STOCH (14,3) : 24.71, STOCH RSI : 0.28, UO : 37.95, Williams %R : -75.29), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AN2 Therapeutics Inc. in the last 12-months were: Capital Management, L.P. Ra (Buy at a value of $16 000 002), Eric Easom (Buy at a value of $53 800), Eric Easom (Sold 87 392 shares of value $1 391 311 )
AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
CEO:
Telephone: +1 650 331-9090
Address: 1800 El Camino Real, Menlo Park 94027, CA, US
Number of employees: 22
